EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Engagement With Daily Symptom Reporting, Passive Smartphone Sensing, and Wearable Device Data Collection During Chemotherapy: Longitudinal Observational Study

Sean McClaine iD, Jennifer Fedor iD, Christianna Bartel iD, Leeann Chen iD, Krina C Durica iD, Carissa A Low iD

JMIR Cancer · 2024

DOI: 10.2196/57347 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JMIR Cancer, 2024. Verfasst von Sean McClaine und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Pittsburgh, Pittsburgh, PA, United States. Hauptthemen laut MEDLINE: Smartphone, Wearable Electronic Devices, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chemotherapy can cause symptoms that impair quality of life and functioning. Remote monitoring of daily symptoms and activity during outpatient treatment may enable earlier detection and management of emerging toxicities but requires patients, including older and acutely ill patients, to engage with technology to report symptoms through smartphones and to charge and wear mobile devices.

Objective

This study aimed to identify factors associated with participant engagement with collecting 3 data streams (ie, daily patient-reported symptom surveys, passive smartphone sensing, and a wearable Fitbit device [Google]) during chemotherapy.

Methods

We enrolled 162 patients receiving outpatient chemotherapy into a 90-day prospective study. Patients were asked to install apps on their smartphones to rate daily symptoms and to collect passive sensor data and to wear a Fitbit device for the duration of the study. Participants completed baseline demographic and quality of life questionnaires, and clinical information was extracted from the electronic medical record. We fit a series of logistic generalized estimating equations to evaluate the association between demographic and clinical factors and daily engagement with each data stream.

Results

Participants completed daily surveys on 61% (SD 27%) of days and collected sufficient smartphone data and wearable sensor data on 73% (SD 35%) and 70% (SD 33%) of enrolled days, respectively, on average. Relative to White participants, non-White patients demonstrated lower odds of engagement with both symptom surveys (odds ratio [OR] 0.49, 95% CI 0.29-0.81; P=.006) and wearable data collection (OR 0.35, 95% CI 0.17-0.73; P=.005). Patients with stage 4 cancer also exhibited lower odds of engagement with symptom reporting than those with earlier stage disease (OR 0.69, 95% CI 0.48-1.00; P=.048), and patients were less likely to complete symptom ratings on the weekend (OR 0.90, 95% CI 0.83-0.97; P=.008). Older patients (OR 1.03, 95% CI 1.01-1.06; P=.01) and those who reported better cognitive functioning at study entry (OR 1.18, 95% CI 1.03-1.34; P=.02) were more likely to engage with Fitbit data collection, and patients who reported higher levels of depressive symptoms were less likely to engage with smartphone data collection (OR 1.18, 95% CI 1.03-1.36; P=.02).

Conclusions

Remote patient monitoring during chemotherapy has the potential to improve clinical management, but only if patients engage with these systems. Our results suggest significant associations between demographic and clinical factors and long-term engagement with smartphone and wearable device assessments during chemotherapy. Non-White participants, those with metastatic cancer, or those with existing cognitive impairment may benefit from additional resources to optimize engagement. Contrary to hypotheses, older adults were more likely than younger adults to engage consistently with wearable device assessments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SmartphoneWearable Electronic DevicesNeoplasmsHumansMaleFemaleMiddle AgedLongitudinal StudiesProspective StudiesAgedQuality of LifeAdultAntineoplastic AgentsData CollectionMobile ApplicationsSurveys and Questionnaires

Stichwörter der Autor:innen

cancerchemochemotherapydigital healthdigital interventionmHealthmetastasesmobile applicationmobile healthmobile phoneoncologyremote monitoringwearable device

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • University of Pittsburgh, Pittsburgh, PA, United States.

ORCID-Profile: Sean McClaine, Jennifer Fedor, Christianna Bartel, Leeann Chen, Krina C Durica, Carissa A Low

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

McClaine, S., Fedor, J., Bartel, C., Chen, L., Durica, K. C., & Low, C. A. (2024). Engagement With Daily Symptom Reporting, Passive Smartphone Sensing, and Wearable Device Data Collection During Chemotherapy: Longitudinal Observational Study. JMIR Cancer. https://doi.org/10.2196/57347

Vancouver

McClaine S, Fedor J, Bartel C, Chen L, Durica KC, Low CA. Engagement With Daily Symptom Reporting, Passive Smartphone Sensing, and Wearable Device Data Collection During Chemotherapy: Longitudinal Observational Study. JMIR Cancer. 2024. doi:10.2196/57347

BibTeX
@article{McClaine2024,
  author = {McClaine, Sean and Fedor, Jennifer and Bartel, Christianna and Chen, Leeann and Durica, Krina C and Low, Carissa A},
  title = {Engagement With Daily Symptom Reporting, Passive Smartphone Sensing, and Wearable Device Data Collection During Chemotherapy: Longitudinal Observational Study},
  journal = {JMIR Cancer},
  year = {2024},
  doi = {10.2196/57347}
}
Kostenlos starten →